NCT03957096: A Safety Study of SGN-CD47M in Patients With Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active central nervous system metastases; Patients with carcinomatous meningitis; Patients with previous exposure to CD47 or SIRPα targeted therapy, Patients with active autoimmune disease

Comments are closed.

Up ↑